China Zhong Qi Holdings Stock (OTC: CHZQ)

Latest news for China Zhong Qi Holdings (OTC:CHZQ) Stock

China Zhong Qi Holdings Ltd is engaged in mining of fluorite. The company is also engaged in equity investment and financial services sector.

CHINA ZHONG QI HLDGS LTD by CHINA ZHONG QI HLDGS LTD.

China Zhong Qi Holdings Ltd

As markets brace for the Federal Reserve's final policy meeting of the year, scheduled at 2:00 p.m. Wednesday, Goldman Sachs highlighted 20 exchange-traded funds (ETFs) that have historically shown outsized <a href="https://www.benzinga.com/topic/federal-reserve">moves around Fed decision days</a>.
While a 25-basis-point rate cut to a target range of 4.25%-4.50% is widely anticipated, the market's focus is on the Fed's forward guidance, particularly the Summary of Economic Projections (SEP) and the updated &#8220;dot plot.&#8221;
Following December's expected cut, Goldman Sachs projects a more measured pace of easing next year, forecasting rate cuts in March, June, and September, with the terminal rate seen at 3.50%-3.75%.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42554114/all-eyes-on-december-fed-meeting-as-traders-await-interest-rate-projections">All Eyes On December Fed Meeting As Traders Await Interest Rate Projections</a>
<h3 class="wp-block-heading">Market Dynamics Around Fed Days</h3>
U.S. equity markets have displayed strong short-term gains during Fed meeting weeks in 2024. 
Investors employing a simple strategy of buying the S&amp;P 500 index at market close before a Federal Open Market Committee (FOMC) announcement and selling at close the following day have captured median returns of 1.1% across the past seven meetings.
Yet those extending the trade horizon to 15 sessions post-Fed meeting have enjoyed significantly larger average gains of 3.29%, more than double the short-term returns. Notably, every Fed meeting this year has resulted in positive 15-day returns.
"We observe that U.S. banking ETFs, such as SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>) and SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>), have seen unusually large moves on FOMC days since 2022" Goldman analysts wrote in a recent note.
For bond-focused investors, the report highlights consistent post-meeting gains in high-yield and investment-grade ETFs like iShares iBoxx $ High Yield Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYG#NYSE">HYG</a>) and iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LQD#NYSE">LQD</a>).
Meanwhile, energy-focused ETFs, such as the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), have seen negative reactions. 
<h3 class="wp-block-heading">ETFs Showing Heightened Fed-Day Moves</h3>
Here's Goldman Sachs' list of 20 ETFs with the largest absolute moves – which include both positive and negative swing – on FOMC days:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF Name</th>
<th>Focus</th>
<th>Average Absolute Move on FOMC since 2022</th>
<th>Average Absolute Move (Last 3 FOMC events)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPDR S&amp;P Regional Banking ETF </td>
<td>Regional Banking</td>
<td>2.5%</td>
<td>1.5%</td>
</tr>
<tr>
<td>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>)</td>
<td>Semiconductor</td>
<td>2.4%</td>
<td>3.7%</td>
</tr>
<tr>
<td>iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>)</td>
<td>Semiconductor</td>
<td>2.4%</td>
<td>3.3%</td>
</tr>
<tr>
<td>SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>)</td>
<td>US Large Banks</td>
<td>2.2%</td>
<td>1.3%</td>
</tr>
<tr>
<td>SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)</td>
<td>Biotech</td>
<td>2.0%</td>
<td>0.3%</td>
</tr>
<tr>
<td>United States Oil Fund </td>
<td>Oil</td>
<td>1.9%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>Technology</td>
<td>1.9%</td>
<td>2.3%</td>
</tr>
<tr>
<td>iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>)</td>
<td>Silver</td>
<td>1.7%</td>
<td>2.4%</td>
</tr>
<tr>
<td>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)</td>
<td>Nasdaq 100</td>
<td>1.7%</td>
<td>1.7%</td>
</tr>
<tr>
<td>Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>Discretionary</td>
<td>1.6%</td>
<td>1.0%</td>
</tr>
<tr>
<td>iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)</td>
<td>Russell 2000</td>
<td>1.5%</td>
<td>0.3%</td>
</tr>
<tr>
<td>SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)</td>
<td>S&amp;P 500</td>
<td>1.2%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>)</td>
<td>S&amp;P 500</td>
<td>1.2%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>Financial</td>
<td>1.1%</td>
<td>0.7%</td>
</tr>
<tr>
<td>SPDR Gold Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>)</td>
<td>Gold</td>
<td>0.9%</td>
<td>1.4%</td>
</tr>
<tr>
<td>iShares J.P. Morgan USD Emerging Markets Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMB#NASDAQ">EMB</a>)</td>
<td>EM Bond</td>
<td>0.8%</td>
<td>0.6%</td>
</tr>
<tr>
<td>iShares iBoxx $ High Yield Corporate Bond ETF </td>
<td>HY Corp Bond</td>
<td>0.6%</td>
<td>0.3%</td>
</tr>
<tr>
<td>iShares iBoxx $ Investment Grade Corporate Bond ETF </td>
<td>IG Corp Bond</td>
<td>0.6%</td>
<td>0.7%</td>
</tr>
<tr>
<td>iShares 7-10 Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEF#NASDAQ">IEF</a>)</td>
<td>7-10 Year Treasury</td>
<td>0.6%</td>
<td>0.7%</td>
</tr>
<tr>
<td>iShares TIPS Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIP#NYSE">TIP</a>)</td>
<td>TIPS Bond</td>
<td>0.5%</td>
<td>0.4%</td>
</tr>
<tr>
<td>Average</td>
<td></td>
<td>1.5%</td>
<td>1.3%</td>
</tr>
</tbody>
</table>
</figure>
Check Out: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42539116/fed-meetings-made-stock-traders-richer-in-2024-could-wednesday-bring-last-big-rally">Fed Meetings Made Stock Traders Richer In 2024: Could Wednesday Bring Last Big Rally?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Specialty ETFs

New ETFs

Emerging Market ETFs

Currency ETFs

Previews

Econ #s

Economics

Federal Reserve

Markets

ETFs

iShares JPMorgan USD Emerging Markets Bond Fund

iShares Trust Barclays 7-10 Year Treasury Bond Fund

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Select Sector SPDR-Consumer Discretionary

20 ETFs Primed For Unusually Big Swings On Fed Meeting Days

Truist Securities analyst Richard Newitter maintains iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) with a Buy and raises the price target from $85 to $111.

News

Price Target

Analyst Ratings

IRTC

Truist Securities Maintains Buy on iRhythm Technologies, Raises Price Target to $111

Citigroup analyst Patrick Cunningham maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and lowers the price target from $70 to $69.

CTVA

Citigroup Maintains Buy on Corteva, Lowers Price Target to $69

Truist Securities analyst Bill Chappell maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Buy and raises the price target from $130 to $150.

Truist Securities Maintains Buy on e.l.f. Beauty, Raises Price Target to $150

Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading higher on Wednesday.</a>
The company, which has gained over 250% over the past year, announced the development of a parallel file system client<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42551250/quantum-announces-support-for-nvidia-gpudirect-storage-with-myriad-all-flash-file-system" rel="noreferrer noopener"> for its Myriad all-flash file system.</a>
This new client is designed to fully enable NVIDIA Corporation GPUDirect Storage capabilities, offering on-the-fly client node deployments with cross-platform compatibility, including support for NVIDIA Grace Hopper ARM-based architectures.
With the development, the company said customers will integrate powerful GPU nodes into their Myriad clusters, responding quickly to the dynamic needs of AI, machine learning, high-performance computing (HPC), and video rendering workflows.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42553957/whats-going-on-with-nikola-stock-today" rel="noreferrer noopener">What&#8217;s Going On With Nikola Stock Today?</a>
The Myriad parallel client transforms host workstations with high-performance GPU cards into operational Myriad GPU nodes, leveraging NVIDIA&#8217;s Magnum I/O technology to bypass CPU bottlenecks.
This direct RDMA data path between storage and GPU memory enables exceptional GPU utilization and performance.
The system is highly flexible, allowing customers to add multiple client nodes to their clusters on-demand and offering connection options like SMB, NFS, and planned S3 access.
Quantum&#8217;s new client is aimed at supporting the growing demands of AI/ML pipelines, offering scalability and adaptability without requiring extensive new infrastructure.
The company is offering the new client for evaluation through its Early Access Program, allowing customers to test and provide feedback.
With this innovation, Quantum is positioning Myriad as a powerful, scalable solution for industries demanding high-performance, data-intensive workflows.
Price Action: QMCO shares are trading higher by 9.40% to $25.95 at last check Wednesday.
Photo via Shutterstock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42526592/bitcoin-ethereum-etfs-see-688m-net-inflows-analysts-target-124000" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum ETFs See $688M Net Inflows, Analysts Target $124,000</a></li>
</ul>

Equities

Movers

Tech

General

QMCO

What's Going On With Quantum Corporation Stock Wednesday?

RBC Capital analyst Rishi Jaluria maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Outperform and raises the price target from $300 to $320.

WDAY

RBC Capital Maintains Outperform on Workday, Raises Price Target to $320

Trading Ideas

NCEW

New Century Logistics Shares Halted On Circuit Breaker To The Downside

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 150 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.36% to 43,607.95 while the NASDAQ rose 0.07% to 20,123.16. The S&amp;P 500 also rose, gaining, 0.12% to 6,058.13.
Check This Out: <a href="https://www.benzinga.com/24/12/42553082/how-to-earn-500-a-month-from-micron-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Information technology shares rose by 0.5% on Wednesday.
In trading on Wednesday, energy shares fell by 0.5%.
Top Headline
The U.S. recorded a current account deficit of $310.9 billion in the third quarter compared to the revised gap of $275.0 billion in the previous period and versus market estimates of a $284 billion gap.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares shot up 273% to $3.9199 after the company announced it secured a GMP partnership with Eurofins CDO Amatsiaquitaine.</li>
<li>Shares of Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) got a boost, surging 200% to $0.5353.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares were also up, gaining 214% to $1.32.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares dropped 49% to $3.24. TransCode Therapeutics announced Safety Review Committee approval of opening third cohort and preliminary results from first cohort in Phase 1 TTX-MC138 clinical trial.</li>
<li>Shares of XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) were down 48% to $12.21.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) was down, falling 46% to $4.0098. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.</li>
</ul>
Commodities In commodity news, oil traded up 1.2% to $70.93 while gold traded down 0.3% at $2,653.10.
Silver traded down 0.7% to $30.700 on Wednesday, while copper rose 0.3% to $4.1580.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 rose 0.2%, Germany's DAX rose 0.2% and France's CAC 40 rose 0.4%. Spain's IBEX 35 Index gained 0.6%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 0.72%, Hong Kong's Hang Seng Index gaining 0.83%, China's Shanghai Composite Index gaining 0.62% and India's BSE Sensex falling 0.62%.
Economics
<ul>
<li>U.S. mortgage applications fell by 0.7% from the previous week during the week ending Dec. 13, compared to the 5.4% gain in the previous week.</li>
<li>The U.S. recorded a current account deficit of $310.9 billion in the third quarter compared to the revised gap of $275.0 billion in the previous period and versus market estimates of a $284 billion gap.</li>
<li>U.S. housing starts fell 1.8% to an annualized rate of 1.289 million units in November from 1.312 million in October.</li>
<li>U.S. building permits in gained by 6.1% to an annualized rate of 1.505 million in November.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42554270/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

CRVS

LITM

NVNI

PLRZ

RNAZ

Dow Surges 150 Points, US Current Account Deficit Widens In Q3

Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and raises the price target from $117 to $118.

Truist Securities Maintains Hold on Zimmer Biomet Holdings, Raises Price Target to $118

Citigroup analyst Patrick Cunningham maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Neutral and lowers the price target from $100 to $73.

Citigroup Maintains Neutral on Celanese, Lowers Price Target to $73

Truist Securities analyst Samuel Brodovsky maintains Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>) with a Buy and raises the price target from $61 to $67.

VCEL

Truist Securities Maintains Buy on Vericel, Raises Price Target to $67

The meme coin space is facing a mix of IP disputes and speculative frenzy as community-driven projects like Neiro (CRYPTO: NEIRO) tokens clash over legitimacy, while Fartcoin (CRYPTO: FARTCOIN)—an AI-inspired meme token—surged to a <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42484464/fartcoin-steals-the-spotlight-from-dogecoin-shiba-inu-to-reach-764-million-all-time-high-market-cap">market cap of $763.9 million</a>.
What Happened: Own The Doge DAO, the organization holding the original Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) meme IP, announced that it has acquired the rights to use the likeness of Neiro.
Neiro is the shiba inu adopted after the passing of Kabosu, the iconic face of the Doge meme.
The DAO is hosting a community discussion to determine which NEIRO-themed token can officially use the dog's image, as multiple tokens on Solana and Ethereum have staked claims.
The announcement follows a wave of NEIRO tokens that emerged after Neiro's adoption, with two projects even reaching hundreds of millions in market capitalization. 
However, Kabosumama, Neiro's owner, made it clear she does not endorse any of these tokens, stating on X, "I do not endorse any crypto project except @ownthedog $DOG because they own the original Doge photo and IP."
This battle over Neiro's image reflects a larger trend in the meme coin world: projects are starting to grapple with intellectual property rights. 
Legal issues are already surfacing, as seen with PNUT (CRYPTO: PNUT), which faced trademark action over its mascot. 
Now, similar risks loom over NEIRO tokens unless consensus and clarity emerge.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42552839/federal-reserve-meeting-preview-3-scenarios-and-what-they-mean-for-bitcoin-ethereum-xrp">Federal Reserve Meeting Preview: 3 Scenarios And What They Mean For Bitcoin, Ethereum, XRP</a>
Why It Matters: While disputes continue over Doge's spiritual successor, another token—Fartcoin—is stealing the spotlight.
The Solana-based project recently hit a market cap of $763.9 million, propelled by <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42484464/fartcoin-steals-the-spotlight-from-dogecoin-shiba-inu-to-reach-764-million-all-time-high-market-cap">viral hype stemming from a Reddit post. </a>
A user shared that her husband invested $175,000 in Fartcoin, humorously justifying his decision with the phrase, "hot air rises."
The story quickly spread across platforms like Twitter, where discussions ranged from amusement to skepticism. 
Some users questioned the token's valuation, while others, like Jacob King, pointed out its size: "BREAKING: Fartcoin&#8217;s market cap has now surged to $643 million, making it larger than 85% of U.S. publicly traded companies."
Fartcoin itself has unconventional roots. 
It was conceptualized by Terminal of Truths, an AI agent funded by a $50,000 Bitcoin grant from Marc Andreessen, with development taking place in a collaborative AI space called Infinite Backrooms.
Initially designed as an experimental funding tool for creative projects like film production and reforestation, the token has now become a centerpiece of speculative trading.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42551036/coinbases-2025-market-outlook-highlights-5-major-trends-to-come">Coinbase&#8217;s 2025 Market Outlook Highlights 5 Major Trends To Come</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Doge Meme IP Owner Acquires New Rights As Fartcoin Continues To Surge

New Century Logistics Shares Resume Trade Following Circuit Breaker Halt

Citigroup analyst Patrick Cunningham downgrades Axalta Coating Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) from Buy to Neutral and lowers the price target from $45 to $41.

Downgrades

AXTA

Citigroup Downgrades Axalta Coating Sys to Neutral, Lowers Price Target to $41

Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) with a Hold and raises the price target from $7 to $8.4.

TMCI

Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $8.4

Stephens &amp; Co. analyst Charles Nabhan upgrades Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) from Equal-Weight to Overweight and raises the price target from $220 to $255.

Upgrades

Stephens & Co. Upgrades Fiserv to Overweight, Raises Price Target to $255

Earnings

NRSN

NeuroSense Therapeutics 9-Month EPS $(0.48) Up From $(0.55) YoY

YSXT

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

WIIM

ACHR

Archer Aviation shares are trading higher after Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $10 to $13.

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $227 to $200.

Comments

China Zhong Qi Holdings

News

Latest news for China Zhong Qi Holdings (OTC:CHZQ) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga